Wednesday, Eli Lilly and Company (LLY) announced results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy.
In SURMOUNT-MAINTAIN trial, both Zepbound MTD and Zepbound 5 mg met the primary and all key secondary endpoints, showing weight-loss maintenance after 60-weeks of initial treatment with Zepbound MTD.
Meanwhile, ATTAIN-MAINTAIN demonstrated that switching to Foundayo also supported long-term weight maintenance, meeting the primary and all key secondary endpoints using both the efficacy estimand and treatment-regimen estimand.
In the pre-market hours, LLY is trading at $988.10, down 0.17 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.